danielle chiesi will pay more than half a million dollars to end the civil fraud charges against her. she pleaded guilty to three criminal counts of conspiracy to commit securities fraud in january and admitted to using her high profile contacts at technology companies to gain insider information. she will be sentenced at the end of this month. >> tom: the kindle could soon be getting a new cousin. published reports say amazon.com will unveil a new tablet computer this fall. the move would help the world's largest internet retailer expand its mobile commerce platforms. it would also allow amazon to better compete with apple's ipad. the "wall street journal" says the tablet will have a nine-inch screen and run google's android operating system. amazon is not commenting. in the last two weeks of june, despite the bad headlines coming out of europe, american investors put more than $1 billion to work in foreign stock mutual funds. tonight's "street critique" guest is going overseas too. she's hilary kramer, editor of gamechangerstocks.com. >> back with us now. your focus now on internati

. >> tom: danielle chiesi, the one-time confidante of convicted hedge fund manager raj rajaratnam, has been sentenced to 2.5 years in prison. chiesi is the first major defendant in the massive insider trading case to be sentenced. prosecutors called her "the consummate wall street insider." rajaratnam was convicted in may. he'll be sentenced in september. technology and health care have been two areas of strength for investors. tonight's "street critique" guest is putting the two together. she's hilary kramer, editor of gamechangerstocks.com. health care plus toj equals biotechnology, and here you look at aria, the ticker symbol up near an 11 year high. what pushes it up into the teens? >> aria pharmaceutical has two important compounds. one is for lung cancer. extremely important, ap 113, and it is other compound is to fight bone sarcomas and skin. it's a joint venture with merck pharmaceutical. in the $12 region. it could go to 18 or $20 because of the huge revenue potential in the applications for other cancers that these two compounds have for aria. >> tom: you've looked at biophar